Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a disorder that involves the activation of alveolar macrophages triggering the innate immune system. The parenchymal lung injury seen in ARDS is a result of many proinflammatory elevations including interleukin-6. There remains no effective standard of c...
Saved in:
Main Authors: | Alessandra Petrillo, Noa Biran, Sean Sadikot |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Critical Care |
Online Access: | http://dx.doi.org/10.1155/2020/8832986 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis
by: Asumi Tada, et al.
Published: (2012-01-01) -
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01) -
Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF-𝛼 Antibody in Mice
by: Masaji Okada, et al.
Published: (2011-01-01) -
Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
by: So Yeong Jeong, et al.
Published: (2025-01-01) -
Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
by: T. Robak, et al.
Published: (1998-01-01)